Golden Child | $37,000,000 | (Apr 29, 2026)
Lighthouse Pharmaceuticals | $12,000,000 | (Apr 29, 2026)
Windmill(US) | $12,000,000 | (Apr 29, 2026)
Nocion Therapeutics, Inc.
United States
- Watertown, MA
- 06/03/2024
- Series B
- $62,000,000
Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons including chronic cough, pain and itch.
- Industry Biotechnology Research
- Website https://www.nociontx.com/
- LinkedIn https://www.linkedin.com/company/nocion-therapeutics-inc/
Related People
Rick BatyckyFounder
United States -
Greater Boston
Experienced Chief Executive Officer with a demonstrated history of working in the biotechnology industry. Strong business development professional skilled in Medical Devices, Biotechnology, U.S. Food and Drug Administration (FDA), Research and Development (R&D), and Life Sciences.
Liquid Instruments | $50,000,000 | (Apr 29, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
Fathom Therapeutics | $47,000,000 | (Apr 28, 2026)
SquareMind | $18,000,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
Iridius | $8,600,000 | (Apr 28, 2026)
Decade Energy | $25,763,540 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)
Cnuic Technologies | $3,000,000 | (Apr 28, 2026)